Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Huntsman Corporation

HUN

NEUTRAL

May 30, 2026

Research Conclusion

Huntsman Corporation (NYSE: HUN) at $14.84 offers modest but no-longer-asymmetric upside in a cyclical chemicals recovery. Probability-weighted fair value is $17–18/share (~15–25% upside) over 24 months. MDI is recovering, restructuring is delivering, and Advanced Materials is durable, but the deep-value frame no longer applies after a ~50% re-rating from $8–12 lows. Patient hold at current price; not a high-conviction add unless specific catalysts (Advanced Materials separation, Rotterdam JV, CBAM extension) confirm. Bear case $9–11 (-35% to -25%); severe downside $3–5.

Company Overview & Moat Assessment

Huntsman Corporation is a global specialty and intermediate chemicals manufacturer headquartered in The Woodlands, Texas, with FY2025 revenue of $5.68B. The company operates three segments: Polyurethanes (~60% of revenue; MDI-based systems for construction, automotive, appliances), Performance Products (~20%; amines, surfactants, specialty chemicals), and Advanced Materials (~20%; aerospace epoxy systems, wind energy resins, electronics). HUN is the smallest Western MDI major (~6–7% global capacity share) with manufacturing in the US (Geismar, Port Neches) and Europe (Rotterdam). The Huntsman family controls ~20% of shares; Peter R. Huntsman is Chairman, President & CEO.

▲ Bull Case

  • MDI cycle recovery accelerates and broadens: NA pricing improvement spreads to Europe/Asia by Q4 2026; global operating rates sustain >90% through 2027; MDI ASPs reach $1,400–1,500/ton; full $100M restructuring savings realized; Polyurethanes margin recovers to 12–13%; 2028E EBITDA $800M+ supports $26–32/share (>75% upside).
  • Advanced Materials separation crystallizes hidden SOTP value: At 12–14x mid-cycle EBITDA of $200M+, Advanced Materials is worth $2.4–2.8B standalone. Spin-off, partial sale, or monetization would remove conglomerate discount and add $3–6/share above operating thesis.
  • Strategic optionality from non-consensus catalysts: Rotterdam JV with Middle Eastern partner, CBAM extension to chemicals, EU anti-dumping duties on Chinese MDI, or industry consolidation would surface value priced as free options at $8–12; remain unpriced even at $14.84.

▼ Bear Case

  • MDI structural impairment from Wanhua: Chinese capacity grows faster than demand; MDI ASPs stagnate or decline through 2027; operating rates stuck at 85–87%; Polyurethanes margin compresses below 5%; 2028E EBITDA falls to $400M; stock retreats to $9–11 (-35% to -25%).
  • European demand/Rotterdam structurally impaired: German recession deepens; Rotterdam runs at marginal cash cost; HUN takes $500M+ impairment on European MDI assets without strategic resolution; EBITDA contribution declines to near zero; net debt rises; dividend cut again.
  • Balance sheet stress in extended trough: If EBITDA falls below $200M for 2+ years while capex remains $150M and interest $90M, FCF turns negative. $429M cash absorbs 2–3 years of burn, but 4-year trough triggers covenant risk or dilutive refinancing; stock can reach $3–5 (-65% to -85%).
Primary Debate on Wall Street

Central debate is 'Cycle vs. Structural': Is current MDI a recoverable cyclical trough (implying 70–100% upside to mid-cycle) or has Wanhua's permanent cost advantage and Chinese state support created a new normal preventing Western producers from earning above WACC (implying current prices are fair-to-rich)? Cycle camp argues: MDI cash cost floor is real; Chinese producers also lose money below $900/ton; Western capacity rationalization (BASF, Covestro mothballing) restores discipline; Q1 2026 NA pricing inflection proves cycle turned. Structural camp argues: Wanhua's $100–200/ton cost advantage is permanent; Chinese government subsidizes through troughs; European de-industrialization is secular; recovery capped by ongoing Chinese additions. Current lean: Cycle camp narrowly favored (55/45) based on Q1 2026 data and cash-cost math, but structural risk is real. At $14.84, stock has substantially priced in the cycle-camp view; further upside requires acceleration of cycle thesis or validation of non-consensus catalyst. Secondary debate: Will management pursue strategic action (Advanced Materials separation, Rotterdam JV) or remain status quo? Status quo delivers ~$17 fair value; activist/family-initiated structural action could deliver $22–28.

Top Catalysts
  • Q2 2026 earnings (August 2026): Confirmation or refutation of sequential MDI ASP improvement; segment EBITDA inflection toward $100M+/quarter
  • MDI global operating rates exceeding 90% sustained for 2+ consecutive quarters
  • Advanced Materials separation announcement (spin, partial sale, or strategic review)
  • Rotterdam strategic resolution: JV with Middle Eastern partner, divestiture, or rationalization
  • CBAM extension to chemicals (EU policy 2027–2028)
  • Industry consolidation announcement: CEO has publicly signaled expectations of M&A and JV activity in 2026–2027
Top Risks
  • MDI ASP recovery stalls or reverses (25–35% probability): NA Q1 2026 signal proves transient; Wanhua adds 1M+ tons capacity; Polyurethanes margin stays at 5–6%
  • European structural impairment (25–35% probability): German recession persists; Rotterdam $500M+ impairment; permanent regional capacity reduction
  • Balance sheet deterioration (15–20% probability): 3+ year trough; FCF turns negative; dilutive financing required
  • Advanced Materials competitive disruption (15–25% probability): Thermoplastic composites take share; aerospace OEMs dual-source; margin compression
  • Governance and family control limits strategic action (ongoing): Chair/CEO + 20% family block prevent activist pressure; status quo persists; SOTP value unlock denied

Full Memo Continues

5 more sections, locked

  • Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/HUN/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.

Huntsman Corporation (HUN) — Investment Memo | Margin of Insight